1 Assessment of COVID-19 vaccine hesitancy among

2 Zimbabweans: A rapid national survey

34

⁵ Paddington T. Mundagowa^{1*¶}, Samantha N. Tozivepi^{1¶}, Edward T. Chiyaka², Fadzai

6 Mukora-Mutseyekwa^{1,6}, Richard Makurumidze^{3,4,5,6}

7 Affiliations

- 8 1. Africa University, College of Health, Agriculture & Natural Science, Clinical
- 9 Research Centre
- 10 2. Kent State University, College of Public Health, Ohio, USA
- 11 3. University of Zimbabwe, Faculty of Medicine and Health Sciences, Public and
- 12 Global Health Unit, Harare, Zimbabwe
- 13 4. Institute of Tropical Medicine, Clinical Sciences Department, Antwerp, Belgium
- 14 5. Free University of Brussels (VUB), Gerontology, Faculty of Medicine &
- 15 Pharmacy, Brussels, Belgium
- 16 6. Zimbabwe College of Public Health Physicians, Harare, Zimbabwe

17

- 18 ***Corresponding Author:** Email: <u>mundagowap@africau.edu</u> (PTM)
- ¹⁹ **[¶]PTM and SNT contributed equally.**

20

22 Abstract

Background: To minimise the devastating effects of the coronavirus disease 2019 (COVID-19) pandemic, scientists hastily developed a vaccine. However, the scale-up of the vaccine is likely to be hindered by the widespread social media misinformation. We, therefore, conducted a study to assess the COVID-19 vaccine hesitancy among Zimbabweans.

Methods: We conducted a descriptive online cross-sectional survey using a selfadministered questionnaire among adults. The questionnaire assessed willingness to be vaccinated; socio-demographic characteristics, individual attitudes and perceptions, effectiveness, and safety of the vaccine. Multivariable logistic regression analysis was utilized to examine the independent factors associated with vaccine uptake.

33 **Results:** We analysed data for 1168 participants, age range of 19-89 years with the majority being females (57.5%). Half (49.9%) of the participants reported that they 34 would accept the COVID-19 vaccine. The majority were uncertain about the 35 effectiveness of the vaccine (76.0%) and its safety (55.0%). About half lacked trust in 36 the government's ability to ensure the availability of an effective vaccine and 61.0% 37 mentioned that they would seek advice from a healthcare worker to vaccinate. Age 55 38 vears and above [vs 18-25 vears - Adjusted Odds Ratio (AOR): 2.04, 95% Confidence 39 Interval (CI): 1.07-3.87], chronic disease [vs no chronic disease - AOR: 1.72, 95%CI: 40 1.32-2.25], males [vs females - AOR: 1.84, 95%CI: 1.44-2.36] and being a healthcare 41 42 worker [vs not being a health worker – AOR: 1.73, 95%CI: 1.34-2.24] were associated with increased likelihood to vaccinate. History of COVID-19 infection [vs no history -43

44 AOR: 0.45, 95%CI: 0.25-0.81) and rural residence [vs urban - AOR: 0.64, 95%CI: 0.40-

45 1.01] were associated with reduced likelihood to vaccinate.

Conclusion: We found half of the participants willing to vaccinate against COVID-19.
The majority lacked trust in the government and were uncertain about vaccine
effectiveness and safety. The policymakers should consider targeting geographical and
demographic groups which were unlikely to vaccinate with vaccine information,
education, and communication to improve uptake.

51

52 **Keywords:** COVID-19, coronavirus, vaccine, hesitancy, willingness, Zimbabwe

53 Introduction

Since the first case of the coronavirus disease (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in 2019, more than three million fatalities and 1.55 billion cases have been recorded globally (1) The healthcare systems have been strained and the adverse socio-economic and psychological impacts are overwhelming (2–4).

Fortunately, more than 100 vaccines have gone beyond the pre-clinical development phase with more than half of these reaching the clinical development phase (5). The herd immunity for SARS-CoV-19 can be reached by vaccinating about 60-72% of the population (6), thus, vaccine acceptance rates will play a major role in combating the pandemic. However, vaccine hesitancy has been recognized as a major threat to the control of vaccine preventable diseases (7). The recent COVID-19 pandemic has caused an outbreak of "infodemics" which has led to rapid and far-reaching spread of

inaccurate information on the COVID-19 vaccine (8). This deluge of unreliable
 information can contribute to COVID-19 vaccine hesitancy despite the availability of
 safe and effective vaccines (9).

Like many other developing countries, Zimbabwe has started the process of securing 69 COVID-19 vaccine. A COVID-19 national deployment and vaccination strategy (10) has 70 been developed and plans for national deployment and training of healthcare workers 71 are underway. In this barrage of infodemics, Zimbabweans have not been spared as 72 conspiracy beliefs filtered through the population, particularly through the different social 73 media platforms. The best way to fight misinformation is through aggressive 74 dissemination of accurate information about the truths of the risks and benefits of 75 76 COVID-19 vaccine.

Evidence on the population's intention to be vaccinated for COVID-19 is limited and 77 public health authorities are confronted with a challenge of objectively discerning the 78 79 truth from the circulating information blast. Understanding the factors influencing vaccine hesitancy is pertinent in crafting targeted communication and interventions to 80 sell the idea of vaccination to specific groups of people. We therefore conducted a 81 national survey to assess COVID-19 vaccine hesitancy among Zimbabweans. We 82 assessed socio-demographic characteristics, individual attitudes and perceptions, 83 Covid-19 vaccine effectiveness and safety, and risks of contracting the COVID-19 in 84 relation to the uptake of the COVID-19 vaccine. 85

86 Methods

87 Study Design

88 We conducted an online descriptive cross-sectional survey in February 2021.

89 Study setting

The study was conducted in Zimbabwe. By the end of 2020, the country had an estimated population of 15.1 million (11). Approximately 99.6% of the population is of African origin and the median age is 18.7 years (12). Geographically, the country is divided into 10 provinces and 63 districts. The first COVID-19 case was recorded on the 20th of March 2020 and according to the Zimbabwean Ministry of Health and Child Care Daily COVID-19 Update Report of the 11th of May 2021, the country had recorded a cumulative of 38 466 cases, 36 277 recoveries, and 1579 deaths (13).

97 Study participants

98 All Zimbabwean residents were eligible to participate in the survey. Considering the 99 online nature of the survey and the easy sharing via social networks, we allowed 100 Zimbabweans out of the country to participate but were excluded from the analysis 101 because (information to inform local context) their COVID-19 vaccine uptake was more likely to be influenced by their current context. We included adults aged 18 years and 102 103 above and those who had participated but below 18 years were excluded. The survey was disseminated mainly via social media networks (WhatsApp and Facebook) hence 104 those registered in those platforms were likely to participate. 105

106

107 Sample size

The minimum sample size was estimated at 423, based on the following assumptions;
95% confidence interval, 5% margin of error, the expected proportion of vaccine uptake

estimated as 52% (14) in the adult population in Zimbabwe and the attrition rate of 10%.

Data collection tools and procedures

112 A multi-item survey questionnaire was developed based on literature review (15,16). The online guestionnaire was designed using Google Forms. The survey guestionnaire 113 114 was developed in English and later translated into the two main local languages in Zimbabwe, Shona and Ndebele. The survey questionnaire comprised of five sections 115 with the first section collecting participant's demographic data (age, sex, residence, 116 educational level, employment status, medical aid status). The second section 117 consisted of questions soliciting information and knowledge on COVID-19 vaccine. The 118 third section sought to assess vaccine uptake, effectiveness and safety. The fourth 119 120 section assessed the risk of contracting COVID-19. We also collected qualitative information through open-ended questions and will be reported separately. 121

Our outcome variable was vaccine uptake in the event that a COVID-19 vaccine becomes available and it had three responses, "Would Accept", "Unsure" and "Would reject". However, for our analysis we combined our responses into binary those that will be vaccinated "Yes" (Would Accept) and those that would not be vaccinated, "No" (Unsure/Would reject). Potential study participants were recruited using random sampling via social media mainly WhatsApp and Facebook through the network and

contacts of the researchers. The researchers encouraged participants to share the online survey with others in their networks as well. The survey was also shared in social media groups for academic and community organizations. Measures were put in place to ensure that the questionnaire was taken only once. Data were collected over a period of 15 days from the 3rd of February 2021 to the 17th of February 2021.

133

134 Statistical Analysis

A database was created in Microsoft Excel using the data extracted from the online 135 server. Responses from the Shona and Ndebele questionnaires were coded into 136 English and then merged into one English database. Data cleaning was done in Excel 137 before exporting it to SPSS for analyses. Statistical analysis was performed using SPSS 138 (V.26.0). Descriptive statistics were conducted using frequencies and proportions and 139 140 were presented in tables and graphs. Logistic regression models were used to examine factors associated with vaccine uptake. Statistical significance was set at p< 0.05 and 141 95% confidence interval. 142

143 **Ethical considerations**

Ethical clearance to carry out this study was obtained from the Medical Research Council of Zimbabwe (MRCZ/A/2714). Informed consent was provided online and all participants were asked to accept or reject participation in the online survey. Participation in this study was voluntary and was not incentivized. All the responses provided during this survey were anonymous.

149 **Results**

150 Study participants

We received 1290 responses during the survey period. In terms of language, the 151 distribution of responses was as follows: 1196 English, 71 Shona and 23 Ndebele. Of 152 the 1290 participants who completed the survey, 122 were excluded from analysis for 153 154 the following reasons (89 were based outside Zimbabwe, 4 were under the age of 18 years, 26 were duplicate responses, and in 3 age was missing). We finally analysed 155 156 1168 participants. The study participants were from all the 10 provinces of Zimbabwe and half (50.5%) were from Harare province which houses the capital city of the 157 158 country.

Socio-demographic characteristics of the study participants

A total of 1168 participants were included in the study with a median age of 39 years 160 (interguartile range; IQR: 32-49) and an age range of 19 – 89 years. Table 1 shows a 161 summary of the socio-demographic characteristics of the participants. The majority of 162 the study participants were in the 36-45 years age group. Females constituted (57.5%) 163 while 36% were health care workers. A significantly higher proportion (92.6%) of 164 165 participants was residing in an urban setting. About 41.2% of the participants reported 166 having at least one chronic condition. More than 90% reported having a good health status and a similar proportion had tertiary education as the highest level of education 167 168 achieved. About 5% reported having tested positive for COVID-19 at some point prior to the survey. Among health care workers, only 6% of them reported having been 169

- diagnosed of COVID-19 prior to the survey. Additionally, about 37.9% of health care
- 171 workers reported having at least one chronic condition (results not shown in the table).
- 172 Table 1 shows a summary of the socio-demographic characteristics of the participants.
- 173 Table 1. Socio-demographic characteristics of survey participants (N = 1,168)

Characteristics	n (%)	Vaccine	e uptake
		Yes (n = 579)	No (n = 589)
Age group (years)			
18-25	125 (10.7)	53 (42.4)	72 (57.6)
26-35	308 (26.4)	141 (45.8)	167 (54.2)
36-45	365 (31.3)	186 (51.0)	179 (49.0)
46-55	214 (18.3)	109 (50.9)	105 (49.1)
>55	156 (13.4)	90 (57.7)	66 (42.3)
Sex			
Male	496 (42.5)	280 (56.5)	216 (43.5)
Female	672 (57.5)	299 (44.5)	373 (55.5)
Health care worker			
Yes	420 (36.0)	234 (55.7)	186 (44.3)
No	748 (64.0)	345 (46.1)	403 (53.9)
Chronic conditions			
Yes	481 (41.2)	276 (57.4)	205 (42.6)
No	687 (58.8)	303 (44.1)	384 (55.9)
Health status			
Good	1054 (90.2)	520 (49.3)	534 (50.7)
Not so good	114 (9.8)	59 (51.8)	55 (48.2)
Tertiary education			
Yes	1102 (94.3)	547 (49.6)	555 (50.4)
No	66 (5.7)	32 (48.5)	34 (51.5)
Residence			
Urban	1081 (92.6)	544 (50.3)	537 (49.7)
Rural	87 (7.4)	35 (40.2)	52 (59.8)
Employment status			
Employed	955 (81.8)	465 (48.7)	490 (51.3)
Not employed	103 (8.8)	58 (56.3)	45 (43.7)
Student	110 (9.4)	56 (50.9)	54 (49.1)
Medical Aid			
Yes	922 (78.9)	460 (49.9)	462 (50.1)
No	246 (21.1)	119 (48.4)	127 (51.6)
Medical Home			
Yes	895 (76.6)	458 (51.2)	437 (48.8)

No	273 (23.4)	121 (44.3)	152 (57.7)
Telehealth access			
Yes	665 (56.9)	341 (51.3)	324 (48.7)
No	503 (43.1)	238 (47.3)	265 (52.7)
Got COVID19			
Yes	57 (4.9)	19 (33.9)	38 (66.7)
No	1111 (95.1)	560 (50.4)	551 (49.6)

174 Uptake of the vaccine

Half (49.9%) of the participants indicated that they would accept the COVID-19 vaccine 175 176 if they are offered when it becomes available, about 31.1% were unsure of whether they 177 would take the vaccine or not and the other 19% indicated that they would reject the vaccine outright. The proportion of vaccine uptake across the different age groups 178 differed. Among adults aged 55 years and older, about 57.9% were willing to get 179 180 vaccinated compared to only 43.9% in the 18-25 years age group. Among health care 181 workers, 56.3% reported having an intention to get vaccinated. Additionally, 57.9% of 182 those who reported having at least one chronic condition expressed willingness to get 183 vaccinated once the vaccine was available. Participants with a tertiary education were 184 indifferent about vaccination with 50% expressing interest. After combining responses 185 on our outcome variable, half (49.9%) of the study participants would accept the 186 vaccine, "Yes" (Would Accept) and the other half (50.1%) would not be vaccinated, "No" 187 (Unsure/Would reject).

188 **Risk of contracting the COVID-19 infection**

Among those who had been previously diagnosed of COVID-19, about 37% indicated that their infection was not so severe, while the other 14% did not experience any

191 severe symptoms due to the infection. Additionally, about 37% indicated that they were 192 not worried of the possibility of re-infection by the virus. Approximately 77% of the 193 participants were worried about the possibility that they might contract the virus, while 194 91% were worried about the possibility that a friend or a relative might catch the virus. 195 Fig 1 shows the perceived risk of contracting COVID-19.

196 Fig 1. Risk of contracting COVID-19

197 Perceived vaccine effectiveness and safety of the COVID-19 vaccine

Approximately 76% of the participants did not think that the vaccine will be effective in reducing symptoms of the virus and another 72% indicated that they did not think that the vaccine will be effective in preventing infection. Slightly more than half (51%) of the participants indicated that they did not trust the government and other relevant authorities in ensuring that the vaccine is effective and safe. Fig 2 shows the perceived effectiveness and safety of the COVID-19 vaccine.

Fig 2. Perceived vaccine effectiveness and safety of the COVID-19 vaccine

205 Decision to be vaccinated with the COVID-19 vaccine

Among factors considered by participants in deciding to get vaccinated or not, we looked at convenience, availability, confidence in vaccine efficacy, vaccine effectiveness, and potential sources of advice. About 58% of the adults indicated that they would strongly consider vaccine effectiveness in their decision-making process. A similar proportion also identified free vaccine access and vaccine safety as important

factors in deciding whether to get vaccinated for COVID-19 or not. Fig 3 shows the preferences of the adults on the different factors assessed.

Fig 3. Decision to be vaccinated with the COVID-19 vaccine

Factors associated with intention to be vaccinated with the COVID-19

215 vaccine

Different covariates were assessed on their association with intention to vaccinate using 216 logistic regression analysis (Table 2). After adjusting for all covariates of interests, 217 adults aged 55 years and older were two times more likely to get vaccinated when 218 219 compared to those aged 18-25 years [Adjusted Odds Ratio (AOR): 2.04, 95% CI: (1.07 - 3.87)]. Similarly, health care workers were 1.73 times more likely to get vaccinated 220 when compared to non-health care workers [AOR: 1.73, [95% CI: (1.34 – 2.24)]. Being 221 222 male [vs female AOR: 1.84, 95% CI: (1.44 – 2.36)] and having at least one chronic condition [vs no chronic condition AOR: 1.72, 95% CI: (1.32 – 2.25)] were significantly 223 associated with intention to vaccinate. Participants who had been previously diagnosed 224 225 of COVID-19 [vs no previous COVID-19 infection AOR: 0.45, 95% CI: (0.25 - 0.81)] 226 were significantly less likely to get vaccinated. Not so good health status, tertiary 227 education, and medical home (having a primary health care doctor) were associated with borderline likelihood of getting vaccinated. We assessed the same covariates 228 229 among the health care workers sub group, and only being male [vs females, AOR: 1.92] 230 95% CI: (1.24 – 2.98)] was associated the likelihood of getting vaccinated.

Table 2. Bivariate and multivariable logistic regression model results

		l Odds Ratio nd 95% Cl	Adjusted Odds Ratio (AOR) and 95% CI			
	UOR	95% CI	AOR	95% CI		
Age group (years)						
18-25	Ref		Ref			
26-35	1.15	0.75 – 1.75	1.57	0.89 – 2.75		
36-45	1.41	0.94 - 2.13	1.84	1.04 – 3.28		
46-55	1.41	0.90 - 2.20	1.75	0.95 – 3.23		
>55	1.85	1.15 – 2.98	2.04	1.07 – 3.87		
Sex						
Female	Ref		Ref			
Male	1.62	1.28 – 2.04	1.84	1.44 – 2.36		
Health care worker						
No	Ref		Ref			
Yes	1.47	1.16 – 1.87	1.73	1.34 – 2.24		
Chronic conditions			-			
No	Ref		Ref			
Yes	1.71	1.35 – 2.16	1.72	1.32 – 2.25		
Health status						
Good	Ref		Ref			
Not so good	0.91	0.62 – 1.34	1.13	0.74 – 1.72		
Tertiary education						
No	Ref		Ref			
Yes	1.05	0.64 – 1.72	1.13	0.66 - 1.91		
Residence						
Urban	Ref		Ref			
Rural	0.66	0.43 - 1.04	0.64	0.40 - 1.01		
Employment status						
Not employed	Ref		Ref			
Student	0.81	0.47 – 1.38	1.24	0.63 – 2.43		
Employed	0.74	0.49 – 1.11	0.63	0.40 - 0.99		
Medical Aid						
No	Ref		Ref			
Yes	1.06	0.80 - 1.41	0.91	0.65 – 1.25		
Medical Home						
No	Ref		Ref			
Yes	1.32	1.00 – 1.73	1.20	0.87 – 1.64		
Telehealth access						
No	Ref		Ref			
Yes	1.17	0.93 – 1.48	1.18	0.92 – 1.51		
Got COVID19						
No	Ref		Ref			
Yes	0.49	0.28 – 0.86	0.45	0.25 – 0.81		

	category		
232			
233			

234 **Discussion**

Our study was the first to assess the COVID-19 vaccine hesitancy at national level in 235 Zimbabwe. The study findings showed that half of the study participants reported that 236 237 they would accept the COVID-19 vaccine if it becomes available. The majority of the survey participants were uncertain about the effectiveness of the vaccine and lacked 238 confidence on the safety of the vaccine. About half lacked trust in the government's 239 240 ability to ensure that the vaccine will be effective and most participants would seek the advice of a healthcare worker first before getting vaccinated. Increased age, presence 241 of chronic disease/condition, male gender and being a healthcare worker were 242 associated with increased likelihood of vaccine acceptance while a history of COVID-19 243 infection and rural residence were associated with reduced likelihood of vaccine 244 245 acceptance.

Our study findings showed that half of the participants (50%) were willing to take the 246 247 COVID-19 vaccine while the other half were either unsure or would reject taking the vaccine. These findings are consistent with other African studies from the Democratic 248 Republic of Congo (DRC) (56%) (17), and Nigeria (50%) (18). The similarities in 249 250 findings may be due to resemblances in the methodology used, as well as socioeconomic and political settings in DRC, Nigeria and Zimbabwe. However, a South 251 African survey showed that about 71% were willing to get vaccinated against COVID-19 252 (19). Based on the significant difference in vaccine acceptance for this study and the 253

254 South African study, one might hypothesize that South Africans were more likely to 255 accept the vaccine given the high numbers of reported COVID-19 cases and fatalities 256 as compared to the other countries (DRC, Nigeria and Zimbabwe).

Moreover, the surveys from DRC, Nigeria and this study were conducted before the 257 vaccine was rolled out and conspiracy theories on the COVID-19 vaccine were at their 258 259 peak thus, the researchers predict an increase in vaccine acceptance as more accurate 260 information penetrates the population, more people getting vaccinated and vaccine effectiveness being witnessed in those who would have been vaccinated. The level of 261 vaccine hesitancy found in our study was low when compared to the required COVID-19 262 herd immunity i.e. 60-70% (20). A COVID-19 vaccine uptake of 50% may not be 263 264 adequate based on Zimbabwean government's plans to vaccinate 60% of the 265 population as a way of reaching the herd immunity threshold (21). Therefore, there is a 266 need to come up with strategies to increase the proportion of citizens willing to get the 267 COVID-19 vaccine. Strategies that have been shown to increase COVID-19 vaccine 268 uptake include engagement of community leaders, social mobilization tactics, mass 269 media campaigns, the use of reminder and follow-up systems, training and education of 270 health care professionals, incentives, vaccine mandates, efforts to make vaccine more 271 accessible, and efforts to increase general knowledge and awareness (22,23).

Healthcare workers who took part in this study were more likely to accept the COVID-19 vaccine and this finding corroborated with a study in the U.S (24). It can be hypothesised that healthcare workers perceived their susceptibility to contract COVID-19 as high as evidenced by a study which reported that healthcare workers had a more than seven-fold higher risk of severe COVID-19 across all occupational groups (25).

medRxiv preprint doi: https://doi.org/10.1101/2021.06.24.21259505; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

277 Since health providers have the moral obligation not to harm their patient (26), they may feel compelled to protect the sick and vulnerable patients by getting vaccinated 278 themselves. This is a decisive finding since healthcare workers' vaccine acceptance can 279 easily untangle vaccine hesitancy when recommending the vaccine to their clients. The 280 health providers can also serve as role models of vaccine acceptance for the general 281 282 population. Efforts to combat COVID-19 vaccine hesitancy among the general 283 population can utilize the increased intention to vaccinate among health workers by making them community outreach vaccine advocates. 284

Most of the study participants doubted the effectiveness of the COVID-19 vaccine. This 285 was consistent with findings from an African study where despite the respondents' 286 287 agreement with the importance of vaccinating the population against SARS-CoV-2, 288 many had reservations about the effectiveness and safety of the vaccine (27). The 289 doubting of the effectiveness could be attributed to several reasons. Firstly, this could 290 be attributed to the lack of information on how the vaccine was developed and tested. There has been concern on how some vaccines were developed with people preferring 291 292 those thought to have been developed transparently in comparison to those whose 293 development was shrouded with secrecy (28,29). Secondly, there were concerns on 294 whether trials were not rushed and regulatory standards relaxed considering the 295 unprecedented speed at which the COVID-19 vaccines were developed (30). The lack 296 of lucid information on vaccine development exacerbates the vaccine hesitancy problem and it is essential for health authorities to be equipped with authentic information on 297 how the COVID vaccines were developed; thus enabling them to disseminate factual 298 299 information and allay the vaccine effectiveness related anxieties.

medRxiv preprint doi: https://doi.org/10.1101/2021.06.24.21259505; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

300 The perceived lack of acceptance of the COVID-19 vaccine in Zimbabwe can partly be attributed to earlier reports on safety of the COVID-19 vaccines with respect to possible 301 side- and adverse effects (31). Some Zimbabweans became sceptical and reserved 302 303 towards the vaccine especially after experts questioned the effectiveness of the vaccines developed before the 501.V2 coronavirus variant which originated from South 304 Africa and appeared to be a more contagious strain infiltrating the country (21). The 305 widespread dissemination of vaccine safety information should be done before rolling 306 out the vaccine to ensure that people make an informed decision based on scientifically 307 308 proven information instead of rumours and conspiracy theories. The health authorities should continue to update citizens about vaccine side-effects and institute strong 309 pharmacovigilant systems as well as, compensation schemes for severe adverse 310 events as this might boost public confidence in vaccine safety (32,33). 311

312 About half of the participants in this study lacked trust on whether the government and 313 relevant authorities would be able to provide a safe vaccine that would protect them 314 from COVID-19. Such public insecurities were also observed in other studies on vaccine 315 hesitancy (34,35). These public insecurities may be caused by unsubstantiated political 316 statements, incapacities of the health system and centralisation of health services. 317 Unscientific claims on COVID-19 by individuals in positions of authority can introduce 318 uncertainties within the population and lower their trust in how the government is 319 handling the pandemic. The Zimbabwean healthcare system is facing serious 320 challenges including shortage of essential drugs, lack of equipment to carry out basic procedures, and skills migration thus, citizens may lack trust in the system's ability to 321 322 contain the pandemic. Despite the proposed free COVID-19 vaccination, there are other

indirect costs that could be incurred by citizens to get to the vaccination sites which are currently centralised at secondary and tertiary health facilities. Travelling costs and loss of productive time could be potential barriers to COVID-19 vaccination in low-income settings like Zimbabwe. Thus, the government should work towards increasing the national health budget to cater for the excess service demand caused by the pandemic. It is also critical to decentralize vaccination sites and to use influential community leaders for community outreach activities.

The current study also revealed that an increase in age and the presence of a chronic 330 condition were associated with a high likelihood of vaccine acceptance. These findings 331 are consistent with findings from other studies that showed a strong association 332 333 between age and willingness to get vaccinated (35,36). The risk of severe COVID-19 334 increases with age and 80% of COVID-19 deaths are of adults 65 years and older (37). 335 Additionally, multiple chronic conditions complicate the progression of COVID-19 (38). 336 Thus, the elderly and those with chronic conditions may have increased perceived 337 vulnerability to the disease and are more likely to take steps towards protecting themselves. 338

We noted that males were more likely to accept the vaccine. Several other studies also revealed similar results (27,28,39–41). This was an unexpected finding given the poor health seeking behaviour among men (42). However, men constitutes the highest proportion of the Zimbabwean workforce and the speculations that some organisations might prioritise or mandate vaccination among their employees to continue productivity in wake of anticipated lockdowns might have influenced men's decision. The reduced vaccine acceptance among women can be attributed to a lack of information of the

medRxiv preprint doi: https://doi.org/10.1101/2021.06.24.21259505; this version posted June 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

346 safety of the vaccine especially with regards to conception related matters; however experts believe that the vaccines were unlikely to pose a risk to pregnant and lactating 347 woman (43). The finding that among the health care worker subgroup, males were also 348 349 likely to be vaccinated than females can be explained by some of the reasons 350 discussed above. Health authorities have the responsibility to give women updated 351 information on the safety of the vaccine during the community outreach activities. It was surprising to note that 39% of those who reported previous COVID-19 infection in this 352 353 study were less likely to be vaccinated. This is despite the fact that those with a history of prior infection could be reinfected by SARS-CoV-2 even after recovering from the 354 initial infection (44). Studies have shown that primary infection only provides short term 355 protective immunity against SARS-CoV-2 (45-47). Individuals who would have 356 357 recovered from coronavirus infection may perceive their susceptibility as low assuming that they would have garnered natural immunity. Although those who have been 358 previously infected by SARS-CoV-2 are less likely to have a repeat infection when 359 360 compared to those without evidence of previous infection, they are still susceptible to reinfection (48), hence, the need to be vaccinated as well. 361

The present study noted that rural residents were less likely to pursue COVID-19 vaccination when compared to those residing in urban areas. This finding corroborates with findings from other similar studies (28,34,49). This could be attributed to poor information penetration and reduced perceived susceptibility risk among the rural folks. The finding can also be explained by the fact that rural residents have reduced health literacy and awareness, reduced trust and interaction with healthcare workers, and presumed cost-based concerns (34,50,51). Information travels faster in urban areas

where mass media and internet connection are readily available thus, it can be easier for those residing in urban areas to access authentic information about the vaccine when compared to most remote rural areas in Zimbabwe. This shows the importance of tailoring vaccine awareness strategies relative to populations residing in varying geographical regions. The authors recommend that policy makers consider geographical- and socio-cultural-specific information for education and communication when approaching the diverse residential settings.

376 Strengths and limitations

Our study assessed a broad range of factors that have been known to influence vaccine 377 acceptance. The findings can be used to guide future health activities with an aim of 378 improving COVID-19 vaccine uptake or uptake of other vaccines. All the ten 379 380 Zimbabwean provinces were represented although some were more represented than others. The data collection tools were distributed in all the three common languages 381 used in Zimbabwe to accommodate the majority of citizens. The study received a fairly 382 383 good response rate, which was unexpected by the researchers given that no incentives were given to cover internet connection fees. The increased use of internet services 384 during the COVID-19 era enabled swift and cost effective online data collection on the 385 386 part of the researchers.

387 Despite the relatively large sample size, the generalizability of our findings can be 388 hampered by our sampling method. The researchers used mainly their social media 389 networks as proxies for distributing the data collection tool. The study was also limited 390 to those who had access to mobile phones, tablets, or computers, thus introducing a

selection bias. We may have excluded the poor and the old who in fact are vulnerable to COVID-19. Besides, the data were collected before the vaccine was rolled out in the country and vaccine hesitancy may have waned as more authentic information became available to the population. The participants were mostly urban dwellers with easy access to internet connection and this could have potentially resulted in a selection bias leaving the rural population. The fact that this study utilized self-reported data makes it vulnerable to reporting bias.

There is a need for further studies to understand how COVID-19 vaccine hesitancy will 398 evolve with time. With the COVID-19 vaccine now available in the country and already 399 being given, studies should be conducted periodically to assess the time-sensitive 400 401 aspect of the vaccine hesitancy among those who rejected the vaccine or were unsure of it. Our study reported the quantitative findings associated with COVID-19 vaccine; 402 403 there is therefore a need for qualitative studies to explore contextual and other 404 individual factors that lead to vaccine hesitancy. Since in our study we were unable to 405 report vaccine hesitancy among targeted sectors of the populations e.g. education, 406 commerce, tourism among others, studies are required to assess how vaccine 407 hesitancy will vary across these sectors. These will enable targeted messaging to 408 improve the vaccine uptake. Though we assessed vaccine hesitancy among health care 409 workers, we were unable to disentangle our data to find out hesitancy among various 410 groups of healthcare workers. Future studies looking into vaccine hesitancy among health care workers should be in position to assess vaccine hesitancy among doctors, 411 nurses, pharmacists and many other healthcare worker professionals. To try and be 412 413 more representative, especially inclusion of the rural communities, future studies should

be conducted physically so that the barrier of access to internet and electronic gadgets
can be bridged. However, strategies to mitigate against COVID-19 infection and spread
should be observed.

417 **Conclusions**

In our study, we found half of the participants were willing to get vaccinated against 418 COVID-19 with the majority lacking trust in the government and being uncertain about 419 420 vaccine effectiveness and safety. The high vaccine acceptance among health workers and the finding that the majority will consult health care workers before deciding to 421 vaccinate, can be a good foundation to launch a successful COVID-19 vaccine 422 awareness campaign in the country. However, the level of vaccination uptake is way 423 below the expected herd immunity hence the government and other relevant authorities 424 should provide timely and accurate information through community-wide campaigns. 425 426 Strategies should also be put in place to target and prioritise groups likely not to vaccinate such as females, younger ages and those without chronic conditions. The 427 428 government and other relevant authorities should aim for a more transparent strategy since it will contribute to public trust and increased acceptability of the vaccine. 429

430 Acknowledgements

The authors would like to thank the following organisations for the support during the study; the University of Zimbabwe, Faculty of Medicine and Health Sciences, Global and Public Health Unit, Africa University, College of Health, Agriculture & Natural Science, Clinical Research Centre (AUCRC) and the Zimbabwe College of Public

Health Physicians (ZCPHP). The authors would like to thank the following individuals
Mandla Tirivavi from AUCRC for administrative support, Brian Maponga and Pamela
Magande from the ZCPHP for facilitating the distribution of the survey and ethical
approval. Finally, we thank all the Zimbabweans who participated in the survey.

439 Authors Contributions

Author	Contribution
Paddington T. Mundagowa	Conceptualisation, Methodology, Investigation, Validation, Writing – original draft preparation, Writing – review & editing
Samantha N. Tozivepi	Conceptualisation, Methodology, Investigation, Data curation, Validation, Writing – original draft preparation, Writing – review & editing
Edward T. Chiyaka	Conceptualisation, Methodology, Formal Analysis, Validation, Writing – original draft preparation, Writing – review & editing
Fadzai Mukora- Mutseyekwa	Conceptualisation, Methodology, Project administration, Supervision, Resources, Funding Acquisition, Writing – review & editing
Richard Makurumidze	Conceptualisation, Methodology, Investigation, Validation, Project administration, Supervision, Writing – original draft preparation, Writing – review & editing

440 **Declarations**

441 Data Availability

The data used during analysis is available from the corresponding author upon a reasonable request.

444 Funding

The study received funding for ethical approval from the Africa University, College of Health, Agriculture & Natural Science, Clinical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

449 **Competing Interests**

The authors declare that they have no competing interests.

451 **References**

- 1. WHO. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2021 [cited 2021 May
- 453 28]. Available from: https://covid19.who.int/
- 454 2. Jahanshahi AA, Dinani MM, Madavani AN, Li J, Zhang SX. The distress of Iranian
- 455 adults during the Covid-19 pandemic More distressed than the Chinese and

456 with different predictors. Brain Behav Immun [Internet]. 2020 Jul;87:124–5.

- 457 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0889159120307121
- 458 3. Mukaetova-Ladinska EB, Kronenberg G. Psychological and neuropsychiatric
- 459 implications of COVID-19. Eur Arch Psychiatry Clin Neurosci [Internet]. 2021 Mar
- 460 22;271(2):235–48. Available from: http://link.springer.com/10.1007/s00406-020-
- 461 01210-2

- 462 4. Morgantini LA, Naha U, Wang H, Francavilla S, Acar Ö, Flores JM, Crivellaro S,
- 463 Moreira D, Abern M, Eklund M, Vigneswaran HT WS. Factors contributing to
- healthcare proffessional burnout during the COVID-19 Pandemic: A rapid
- 465 turnaround global survey. PLoS One. 2020;15(9).
- 466 5. WHO. Draft Landscape of COVID-19 Candidate Vaccines [Internet]. Geneva;
- 467 2021. Available from: https://www.who.int/publications/m/item/draft-landscape-of-
- 468 covid-19-candidate-vaccines
- 6. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd
- immunity to SARS-CoV-2 infection by mass vaccination. Lancet [Internet]. 2020
- 471 Nov;396(10263):1614–6. Available from:
- 472 https://linkinghub.elsevier.com/retrieve/pii/S0140673620323187
- 473 7. WHO. Ten threats to global health in 2019 [Internet]. World Health Organization.
- 474 2019 [cited 2021 May 28]. Available from: https://www.who.int/news-
- 475 room/spotlight/ten-threats-to-global-health-in-2019
- 8. WHO. Infodemic management- infodermiology [Internet]. World Health
- 477 Organization. 2020 [cited 2021 Jan 19]. Available from:
- 478 https://www.who.int/teams/risk-communication/infodemic-msnsgement
- 479 9. MacDonald NE. Vaccine hesitancy: Definition, scope and determinants. Vaccine
- 480 [Internet]. 2015 Aug;33(34):4161–4. Available from:
- 481 https://linkinghub.elsevier.com/retrieve/pii/S0264410X15005009
- 482 10. MoHCC. COVID-19 vaccination gets traction [Internet]. Ministry of Health and
- 483 Child Care, Zimbabwe. 2021 [cited 2021 Jan 19]. Available from:
- 484 http://www.mohcc.gov.zw/index.php?option=com_content&view=article&id=355:c

485 ovid-19-vaccination-gets-traction&catid=84&Itemid=435

- 11. Worldometer. Zimbabwe population 2021 [Internet]. Worldometer. 2021 [cited
- 487 2021 May 28]. Available from: https://www.worldometers.info/world-
- 488 population/zimbabwe-population/#:~:text=Zimbabwe 2020 population is
- 489 estimated, year according to UN data.
- 490 12. ZIMSTAT. Census 2012 Preliminary Report. Harare; 2012.
- 491 13. Ministry of Health and Child Care(MoHCC). Situation report COVID-19,
- 492 Zimbabwe. Harare; 2021.
- 14. Topline Research Solutions. Zimbabweans opinion survey: How best to assist the
- 494 COVID 19 situation in Zimbabwe [Internet]. Harare; 2020. Available from:
- 495 https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahU
- 496 KEwj5ieON1fTwAhWFGuwKHeoCBWIQFjABegQIAxAD&url=https%3A%2F%2Ft
- 497 opliners.co.za%2Fwp-content%2Fuploads%2F2021%2F01%2FProject-Hondo-
- 498 FINAL-Report-14-Jan-2021.pdf&usg=AOvVaw2pLvgfxJPnqKi4xAlg
- Lin C, Tu P, Beitsch LM. Confidence and receptivity for covid-19 vaccines: A rapid
 systematic review. Vaccines. 2021;9(1):1–32.
- 16. COVID Collaborative. Coronavirus Vaccine Hesitancy in Black and Latinx
- 502 Communities [Internet]. COVID Collaborative. 2020 [cited 2021 Jun 6]. Available
- 503 from: https://www.covidcollaborative.us/content/vaccine-treatments/coronavirus-
- 504 vaccine-hesitancy-in-black-and-latinx-communities
- 17. Ditekemena JD, Nkamba DM, Mutwadi A, Mavoko HM, Siewe Fodjo JN, Luhata
- 506 C, et al. COVID-19 Vaccine Acceptance in the Democratic Republic of Congo: A
- 507 Cross-Sectional Survey. Vaccines [Internet]. 2021 Feb 14;9(2):153. Available

- 508 from: https://www.mdpi.com/2076-393X/9/2/153
- 18. Tobin E, Okonofua M, Azeke A, Ajekweneh V, Akpede G. Willingness to
- 510 acceptance a COVID-19 vaccine in Nigeria: a population-based cross-sectional
- 511 study. J Med Res. 2021;5(2):1–6.
- 19. Monama T. 71% of South Africans are willing to take the COVID-19 vaccine
- 513 [Internet]. 2021. Available from:
- 514 https://www.news24.com/news24/southafrica/news/71-of-south-africans-are-
- 515 willing-to-take-the-covid-19-vaccine-study-20210512
- 516 20. Wang W, Wu Q, Yang J, Dong K, Chen X, Bai X, et al. Global, regional, and
- 517 national estimates of target population sizes for covid-19 vaccination: descriptive
- 518 study. BMJ [Internet]. 2020 Dec 15;m4704. Available from:
- 519 https://www.bmj.com/lookup/doi/10.1136/bmj.m4704
- 520 21. Mavhunga C. Government urges Zimbabweans to accept COVID-19 Vaccine.
- 521 VOA News [Internet]. 2021 Feb 13; Available from:
- 522 https://www.voanews.com/covid-19-pandemic/government-urges-zimbabweans-
- 523 accept-covid-19-vaccine
- 524 22. Jarrett C, Wilson R, O'Leary M, Eckersberger E, Larson HJ. Strategies for
- addressing vaccine hesitancy A systematic review. Vaccine [Internet]. 2015
- 526 Aug;33(34):4180–90. Available from:
- 527 https://linkinghub.elsevier.com/retrieve/pii/S0264410X15005046
- 528 23. Gayle H, Foege W, Brown L, Kahn B. Framework for Equitable Allocation of
- 529 COVID-19 Vaccine: Achieving Acceptance of COVID-19 Vaccine. National
- 530 Academies of Sciences, Engineering, and Medicine. 2020.

- 531 24. Shaw J, Stewart T, Anderson KB, Hanley S, Thomas SJ, Salmon DA, et al.
- 532 Assessment of US Healthcare Personnel Attitudes Towards Coronavirus Disease
- 533 2019 (COVID-19) Vaccination in a Large University Healthcare System. Clin
- Infect Dis [Internet]. 2021 Jan 25; Available from:
- https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab054/6118651
- 536 25. Mutambudzi M, Niedzwiedz C, Macdonald EB, Leyland A, Mair F, Anderson J, et
- al. Occupation and risk of severe COVID-19: prospective cohort study of 120 075
- 538 UK Biobank participants. Occup Environ Med [Internet]. 2021 May;78(5):307–14.
- 539 Available from: https://oem.bmj.com/lookup/doi/10.1136/oemed-2020-106731
- 540 26. Gur-Arie R, Jamrozik E, Kingori P. No Jab, No Job? Ethical Issues in Mandatory
- 541 COVID-19 Vaccination of Healthcare Personnel. BMJ Glob Heal [Internet]. 2021
- 542 Feb 17;6(2):e004877. Available from:
- 543 https://gh.bmj.com/lookup/doi/10.1136/bmjgh-2020-004877
- 27. Africa Centres for Disease Control and Prevention, London School of Hygiene
- and Tropical Medicine's Vaccine Confidence Project, Orb International. COVID 19
- 546 Vaccine Perceptions: A 15 country study. 2021;(February):1–70.
- 547 28. El-Elimat T, AbuAlSamen MM, Almomani BA, Al-Sawalha NA, Alali FQ.
- 548 Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study
- 549 from Jordan. medRxiv [Internet]. 2020;(816):1–15. Available from:
- 550 http://dx.doi.org/10.1371/journal.pone.0250555
- 551 29. Pogue K, Jensen JL, Stancil CK, Ferguson DG, Hughes SJ, Mello EJ, et al.
- 552 Influences on Attitudes Regarding Potential COVID-19 Vaccination in the United
- 553 States. Vaccines [Internet]. 2020 Oct 3;8(4). Available from:

- http://www.ncbi.nlm.nih.gov/pubmed/33022917
- 30. Shah A, Marks PW, Hahn SM. Unwavering Regulatory Safeguards for COVID-19
- 556 Vaccines. JAMA [Internet]. 2020 Sep 8;324(10):931. Available from:
- 557 https://jamanetwork.com/journals/jama/fullarticle/2769421
- 558 31. Everington K. Full list of adverse reactions from China's Sinopharm vaccine
- revealed. Taiwan News [Internet]. 2021 Jan 11; Available from:
- 560 https://www.taiwannews.com.tw/en/news/4098913
- 32. Chandler RE. Optimizing safety surveillance for COVID-19 vaccines. Nat Rev
- 562 Immunol [Internet]. 2020 Aug 17;20(8):451–2. Available from:
- 563 http://www.nature.com/articles/s41577-020-0372-8
- 33. Halabi S, Heinrich A, Omer SB. No-Fault Compensation for Vaccine Injury The
- 565 Other Side of Equitable Access to Covid-19 Vaccines. N Engl J Med [Internet].
- 566 2020 Dec 3;383(23):e125. Available from:
- 567 http://www.nejm.org/doi/10.1056/NEJMp2030600
- 568 34. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM.
- 569 Attitudes Toward a Potential SARS-CoV-2 Vaccine. Ann Intern Med [Internet].
- 570 2020 Dec 15;173(12):964–73. Available from:
- 571 https://www.acpjournals.org/doi/10.7326/M20-3569
- 572 35. Soares P, Rocha JV, Moniz M, Gama A, Laires PA, Pedro AR, et al. Factors
- associated with COVID-19 vaccine hesitancy. Vaccines. 2021;9(3):1–14.
- 574 36. Lazarus J V., Wyka K, Rauh L, Rabin K, Ratzan S, Gostin LO, et al. Hesitant or
- 575 Not? The Association of Age, Gender, and Education with Potential Acceptance
- of a COVID-19 Vaccine: A Country-level Analysis. J Health Commun [Internet].

577 2020 Oct 2;25(10):799–807. Available from:

578 https://www.tandfonline.com/doi/full/10.1080/10810730.2020.1868630

579 37. CDC. Older Adults at greater risk of requiring hospitalization or dying if diagnosed

with COVID-19 [Internet]. Center for Disease Control and Prevention. 2021.

- 581 Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-
- 582 precautions/older-adults.html
- 38. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A
- comparison with young and middle-aged patients. J Infect [Internet]. 2020
- 585 Jun;80(6):e14–8. Available from:

586 https://linkinghub.elsevier.com/retrieve/pii/S016344532030116X

- 39. Alqudeimat Y, Alenezi D, AlHajri B, Alfouzan H, Almokhaizeem Z, Altamimi S, et
- al. Acceptance of a COVID-19 Vaccine and its Related Determinants among the

589 General Adult Population in Kuwait. Med Princ Pract [Internet]. 2021 Jan 22;

590 Available from: https://www.karger.com/Article/FullText/514636

40. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19

vaccine acceptance in the US. EClinicalMedicine [Internet]. 2020 Sep;26:100495.

- 593 Available from: https://linkinghub.elsevier.com/retrieve/pii/S258953702030239X
- 41. Wong LP, Alias H, Wong P-F, Lee HY, AbuBakar S. The use of the health belief
- 595 model to assess predictors of intent to receive the COVID-19 vaccine and
- willingness to pay. Hum Vaccin Immunother [Internet]. 2020 Sep 1;16(9):2204–
- 597 **14. Available from:**
- 598 https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1790279
- 42. Mufunda E, Albin B, Hjelm K. Differences in Health and Illness Beliefs in

- Zimbabwean Men and Women with Diabetes. Open Nurs J [Internet]. 2012 Aug
- 601 6;6:117–25. Available from: http://benthamopen.com/ABSTRACT/TONURSJ-6-
- 602 **117**
- 43. CDC. COVID-19 Vaccines While Pregnant or Breastfeeding [Internet]. Center for
- Disease Control and Prevention. 2021 [cited 2021 May 28]. Available from:
- 605 https://www.cdc.gov/coronavirus/2019-
- 606 ncov/vaccines/recommendations/pregnancy.html
- 44. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al.
- 608 Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect
- Dis [Internet]. 2021;21(1):52–8. Available from: http://dx.doi.org/10.1016/S1473-
- 610 **3099(20)30764-7**
- 45. Abu-Raddad LJ, Chemaitelly H, Malek JA, Ahmed AA, Mohamoud YA,
- 412 Younuskunju S, et al. Assessment of the Risk of Severe Acute Respiratory
- 613 Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure
- 614 Setting. Clin Infect Dis. 2020;2.
- 46. Edridge E, Kaczorowska J, Hoste A, Baker M, Klein M, Loens K, et al. Seasonal
- 616 coronavirus protective immunity is short-lasting. Nat Med. 2020;11:1691–3.
- 47. McMahon A, Robb NC. Reinfection with SARS-CoV-2: Discrete SIR (Susceptible,
- Infected, Recovered) Modeling Using Empirical Infection Data. JMIR Public Heal
- 619 Surveill [Internet]. 2020 Nov 16;6(4):e21168. Available from:
- 620 http://publichealth.jmir.org/2020/4/e21168/
- 48. Letizia AG, Ge Y, Vangeti S, Goforth C, Weir DL, Kuzmina NA, et al. Articles
- 622 SARS-CoV-2 seropositivity and subsequent infection risk in healthy young

623	adults⊡: a	prospective	cohort study	. Lancet Resp	ir [Internet]. 2021;2600	(21):1-9.
-----	------------	-------------	--------------	---------------	--------------	--------------	-----------

- 624 Available from: http://dx.doi.org/10.1016/S2213-2600(21)00158-2
- 49. Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ.
- 626 COVID-19 Vaccination Hesitancy in the United States: A Rapid National
- Assessment. J Community Health [Internet]. 2021 Apr 3;46(2):270–7. Available
- 628 from: http://link.springer.com/10.1007/s10900-020-00958-x
- 50. Ferdinand KC, Nedunchezhian S, Reddy TK. The COVID-19 and Influenza
- 630 "Twindemic": Barriers to Influenza Vaccination and Potential Acceptance of
- 631 SARS-CoV2 Vaccination in African Americans. J Natl Med Assoc [Internet]. 2020
- 632 Dec;112(6):681–7. Available from:
- https://linkinghub.elsevier.com/retrieve/pii/S0027968420304089
- 51. Quinn SC, Jamison AM, Freimuth V. Communicating Effectively About
- 635 Emergency Use Authorization and Vaccines in the COVID-19 Pandemic. Am J
- Public Health [Internet]. 2021 Mar;111(3):355–8. Available from:
- https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2020.306036

638

639

640

Apart from yourself, how worried are you, if at all, about the possibility that some of your close friends or family members might catch the coronavirus?				67%			2	24%	6% <mark>3%</mark>
How worried are you, if at all, about the possibility that you might catch the coronavirus?		2	45%			32%	6	16%	8%
How worried are you, if at all, about the possibility that you might catch the coronavirus again?		26%			37%		19%		18%
How severe was your case of the coronavirus?	5%		44%	6			37%		14%
	9% 10 what	/0 _0		0% 40 Not at al		0% 60%	5 70%	80% 9	0% 100%

How well do you trust the government and other relevant authorities will ensure that the vaccine will be effective and safe?		26%	22	%	37%	14	4%
How confident are you that a coronavirus vaccine will be adequately tested for safety and effectiveness?	2'	1%	24%		37%	18	%
How effective do you think a vaccine will be in preventing people from catching the coronavirus?	10%	18%	6	53%	6	199	% Very well Somewhat
How effective do you think a vaccine will be in reducing symptoms if people catch the coronavirus?	9%	15%		50%		26%	Not at all
If you got the COVID-19 vaccine, how likely do you think it , is that you would experience side effects?	3 <mark>%</mark> 1	6%		53%		28%	
If you had side effects, how severe do you think they , would be?	3%	26%		46%		26%	
0	%	209	% 4	0%	60%	80%	100%

Advice from your healthcare provider	35%	26%	17%	5 <mark>8%</mark> 8%
Convenience in where you can get the vaccine	41%	21%	16%	<mark>8%</mark> 13%
Vaccine being available for free	40%	19%	16%	<mark>9%</mark> 15%
Confidence in the vaccine's safety	35%	23%	21%	<mark>8%</mark> 13%
Confidence in the vaccine's effectiveness	33%	25%	23%	8% 11%
Advice from people you trust	25%	28%	28%	<mark>9%</mark> 11%
Other people in your community getting vaccinated	23%	25%	24% 1:	<mark>3%</mark> 16%
09	% 10% 20% 30	0% 40% 50%	60% 70%	80% 90% 10
Extremely Ver	ry ■Somewhat ■I	Not so ■Not at a	I	